CANCER RESEARCH

Scope & Guideline

Fueling the fight against cancer through rigorous research.

Introduction

Welcome to your portal for understanding CANCER RESEARCH, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0008-5472
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1941 to 2024
AbbreviationCANCER RES / Cancer Res.
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

CANCER RESEARCH is dedicated to advancing our understanding of cancer through innovative research and clinical studies. The journal encompasses a wide range of topics related to cancer biology, treatment, and prevention, contributing to the global effort to combat cancer.
  1. Cancer Biology and Mechanisms:
    Research exploring the molecular and cellular mechanisms underlying cancer initiation, progression, and metastasis, including studies on genetic mutations, epigenetic alterations, and the tumor microenvironment.
  2. Therapeutic Strategies and Drug Development:
    Investigations into novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments, aimed at improving clinical outcomes for cancer patients.
  3. Biomarkers and Prognostic Indicators:
    Studies focused on identifying and validating biomarkers that can predict cancer progression, treatment response, and patient prognosis, aiding in personalized medicine.
  4. Clinical Trials and Translational Research:
    Reports on clinical trials evaluating new treatments, surgical techniques, and interventions, bridging the gap between laboratory research and patient care.
  5. Cancer Epidemiology and Risk Factors:
    Research analyzing epidemiological data to identify risk factors associated with various cancer types, contributing to prevention strategies and public health initiatives.
  6. Innovative Methodologies:
    Development and application of cutting-edge techniques, such as machine learning, genomic sequencing, and advanced imaging, to enhance cancer research and diagnostics.
CANCER RESEARCH is at the forefront of addressing emerging themes in cancer research, reflecting the latest advancements in technology, treatment, and understanding of cancer biology.
  1. Immunotherapy and Immune Microenvironment:
    A significant increase in studies focusing on immunotherapy, including checkpoint inhibitors and CAR T-cell therapy, as researchers explore the immune landscape's role in cancer progression and treatment response.
  2. Targeted Therapy and Precision Medicine:
    Emerging research on targeted therapies that exploit specific genetic alterations within tumors, alongside studies on biomarkers for patient stratification and personalized treatment plans.
  3. Role of Non-Coding RNAs:
    A growing body of literature investigating the functions of long non-coding RNAs (lncRNAs) and microRNAs in cancer biology, particularly their roles in regulating gene expression, cancer stemness, and treatment resistance.
  4. Metabolic Reprogramming in Cancer:
    Research focusing on the metabolic adaptations of cancer cells, including the study of pathways like glycolysis and ferroptosis, as potential targets for therapeutic intervention.
  5. Multi-Omics Approaches:
    An increase in studies utilizing multi-omics strategies (genomics, transcriptomics, proteomics) to gain comprehensive insights into cancer biology and identify novel therapeutic targets.

Declining or Waning

While CANCER RESEARCH continues to cover a broad spectrum of cancer-related topics, certain themes have seen a decline in prominence over recent years, reflecting shifts in research focus and clinical priorities.
  1. Traditional Chemotherapy Studies:
    Research centered on conventional chemotherapy regimens has decreased as newer targeted therapies and immunotherapies gain traction, leading to a shift in focus toward more personalized and effective treatment modalities.
  2. Basic Research on Non-Malignant Conditions:
    Investigations into benign tumors and non-cancerous conditions have become less frequent, as the journal prioritizes research that directly impacts cancer treatment and understanding.
  3. Single-Agent Drug Studies:
    The prevalence of studies evaluating the efficacy of single-agent drugs has waned, with a growing emphasis on combination therapies and multi-targeted approaches to overcome resistance and enhance treatment outcomes.

Similar Journals

Breast Cancer-Targets and Therapy

Empowering healthcare through cutting-edge breast cancer research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1314Frequency: 1 issue/year

Breast Cancer-Targets and Therapy is a leading journal in the field of oncology, published by DOVE MEDICAL PRESS LTD in New Zealand. Established as an Open Access journal in 2009, it offers a platform for researchers and healthcare professionals to disseminate innovative findings and therapeutic strategies related to breast cancer. With an impressive ranking in the Q2 category of oncology journals as of 2023, and placed at Rank #203/404 in the Scopus database, this journal facilitates the exchange of high-quality research aimed at improving patient outcomes and advancing clinical practices. Covering a wide array of topics from basic research to clinical trials, Breast Cancer-Targets and Therapy plays a crucial role in bridging the gap between scientific discovery and practical application. Researchers, professionals, and students alike will find the journal a valuable resource for the latest advancements and best practices in breast cancer treatment.

CLINICAL & EXPERIMENTAL METASTASIS

Exploring the Frontiers of Cancer Metastasis
Publisher: SPRINGERISSN: 0262-0898Frequency: 6 issues/year

CLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.

Cancer Research Communications

Advancing the frontiers of cancer knowledge.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Molecular & Cellular Oncology

Innovating therapeutic interventions for a brighter future.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Journal of Cancer Metastasis and Treatment

Empowering researchers with vital oncology knowledge.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

CANCER INVESTIGATION

Exploring the frontiers of cancer research with precision.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

MOLECULAR CANCER THERAPEUTICS

Elevating the standards of cancer therapeutics.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Connecting Research, Treatment, and Future Directions in Oncology
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

CURRENT CANCER DRUG TARGETS

Exploring the latest breakthroughs in cancer drug targets.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Gastric Cancer

Pioneering Research in Gastric Oncology.
Publisher: SPRINGERISSN: 1436-3291Frequency: 4 issues/year

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.